ライフサイエンスコーパス: low-density lipoprotein receptor

1 s primarily dependent on endocytosis via the low density lipoprotein receptor.

2 e expression for lipoprotein lipase and very-low-density lipoprotein receptor.

3 id not bind to the frizzled (Fz) receptor or low-density lipoprotein receptor.

4 esis, and inhibits cholesterol uptake by the low-density lipoprotein receptor.

5 t mice (0.162 cm(2)+/-0.023 [n=9], P2X7(-/-) low density lipoprotein receptor(-/-) : 0.084 cm(2)+/-0.

6 tack complex domain (FIMAC), CD5 domain, and low density lipoprotein receptor 1 (LDLr1) and LDLr2 dom

7 and (99m)Tc-labeled anti-lectinlike oxidized low-density lipoprotein receptor 1 antibody, which detec

8 ibody, which detects the lectinlike oxidized low-density lipoprotein receptor 1 that is overexpressed

9 Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a pattern-

10 Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one of the s

11 LOX-1 (lectin-like oxidized low-density lipoprotein receptor-1), a membrane protein

12 Hepatic clearance of remnants occurs via low density lipoprotein receptors and the heparan sulfat

13 Mice deficient for both the low-density lipoprotein receptor and Apobec-1 were studi

14 Mice deficient for the low-density lipoprotein receptor and Apobec-1 were studi

15 CIH down-regulated hepatic low-density lipoprotein receptor and HMG-CoA reductase e

16 Reversa mice, which are deficient in the low-density lipoprotein receptor and in which hyperchole

17 lesterol lowering, with the discovery of the low-density lipoprotein receptor and its physiology and

18 role for both a t-PA receptor, most likely a low-density lipoprotein receptor, and a plasminogen rece

19 h ER stress and aortic lesion development in low-density lipoprotein receptor- and AMPKalpha2-deficie

20 rotein, plasma for high-density lipoprotein; low-density lipoprotein receptor, APOE and APOB for low-

21 n that the longer Sepp1 isoforms bind to the low density lipoprotein receptor apoER2, but the mechani

22 ADH is caused by mutations in the low-density lipoprotein receptor, apolipoprotein B, or p

23 che within macrophage by modulating oxidized low-density lipoprotein receptor CD36, phagolysosomal ma

24 forms showed that the amino-terminal modular low-density lipoprotein receptor class A (LA) domains wi

25 thylglutaryl-coenzyme A reductase, and human low-density lipoprotein receptor), compared to uninfecte

26 the inflamed aorta in atherosclerosis-prone low-density lipoprotein receptor deficient (Ldlr(-/-)) m

27 arrow-restricted deletion of DNGR-1 in Ldlr (low-density lipoprotein receptor)-deficient mice (Ldlr(-

28 y of Nur77 on atherosclerosis was studied in low density lipoprotein receptor-deficient (Ldlr(-/-)) m

29 Low-density lipoprotein receptor-deficient (Ldlr(-/-) )

30 tic lesions and spleens of high-fat diet-fed low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

31 herosclerotic lesions from high-fat diet-fed low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

32 Lethally irradiated, atherosclerosis-prone, low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

33 Male low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

34 Tet2-mutant cells in atherosclerosis-prone, low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

35 In low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

36 ate senescent cells in atherosclerosis-prone low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

37 od vessels invading photoreceptors: the very low-density lipoprotein receptor-deficient (Vldlr(-/-) )

38 PGES-1-KOs) were crossed into hyperlipidemic low-density lipoprotein receptor-deficient animals.

39 In a low-density lipoprotein receptor-deficient atherosclerot

40 Herein, in low-density lipoprotein receptor-deficient hyperlipidemi

41 Low-density lipoprotein receptor-deficient LDLr(-/-) mic

42 mplement pathways have been shown to protect low-density lipoprotein receptor-deficient mice (Ldlr(-/

43 the liver of diet-induced insulin-resistant low-density lipoprotein receptor-deficient mice and of g

44 lammation and reduced steatosis in livers of low-density lipoprotein receptor-deficient mice fed a We

45 results in decreased hepatic inflammation in low-density lipoprotein receptor-deficient mice on a Wes

46 ress as prime response pathways in livers of low-density lipoprotein receptor-deficient mice on a Wes

47 luence the development of atherosclerosis in low-density lipoprotein receptor-deficient mice.

48 In the AngII-infused hyperlipidemic low-density lipoprotein receptor-deficient mouse (LDLR(-

49 erosclerosis and insulin resistance in mice, low-density lipoprotein receptor-deficient, S100A9-defic

50 subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein receptor, escorting it to its de

51 lipoproteins depends on heparan sulfate and low density lipoprotein receptors expressed on the basal

52 element binding protein 2 and downregulating low-density lipoprotein receptor expression.

53 -related protein 1 (LRP1) is a member of the low density lipoprotein receptor family and plays import

54 n, and alpha-AP-2 and directs endocytosis of low density lipoprotein receptor family members by recog

55 olecular chaperone that binds LRP1 and other low density lipoprotein receptor family members in the e

56 to decreased expression or redistribution of low density lipoprotein receptor family proteins.

57 s a specialized chaperone for members of the low density lipoprotein receptor family.

58 oprotein receptor (VLDLR) is a member of the low-density lipoprotein receptor family that binds multi

59 ined that ER liposomes utilize scavenger and low-density lipoprotein receptors for endocytosis and en

60 -related protein 1 (LRP1) is a member of the low-density lipoprotein receptor gene family found in ne

61 levels by raising the expression of SREBP2, low-density lipoprotein receptor, HMGCo-A reductase, and

62 nvertase subtilisin kexin 9 (PCSK9) binds to low-density lipoprotein receptors, increasing serum LDL-

63 the in vivo models of C57BL/6 wild-type and low density lipoprotein receptor knock-out (LDLR(-/-)) m

64 when Foxo1(KR/KR) mice are intercrossed with low density lipoprotein receptor knock-out mice (Ldlr(-/

65 ow density lipoprotein cholesterol (LDLc) in low density lipoprotein receptor knockout (LDLR(-/-)) mi

66 of G5-PEG and PB-NLCs were investigated in a low density lipoprotein receptor knockout (LDLr-/-) mous

67 vels by 22 and 31%, respectively, in fasting low-density lipoprotein receptor knockout (LDLR(-/-)) mi

68 Cholesterol-fed low-density lipoprotein receptor knockout (LDLR(-/-)) mi

69 hages in advanced atherosclerotic lesions of low-density lipoprotein receptor knockout (LDLR(-/-)) mi

70 found that genetic deletion of AMPKalpha2 in low-density lipoprotein receptor knockout (LDLr(-/-)) st

71 ECGs were measured in low-density lipoprotein receptor knockout (LDLr(-/-)), a

72 in ovalbumin- (OVA-) sensitized C57BL/6 and low-density lipoprotein receptor knockout mice (LDLr(-/-

73 of atherogenesis by mPGES-1 deletion in the low-density lipoprotein receptor knockout mice (n=17-21)

74 In this study, we fed low-density lipoprotein receptor knockout mice a Western

75 Adoptive transfer of apop(ox)-DCs into low-density lipoprotein receptor knockout mice either be

76 and vascular leakage in the eyecups of very low-density lipoprotein receptor knockout mice, a model

77 ncreased atherosclerotic lesion formation in low-density lipoprotein receptor knockout mice.

78 inhibits atherosclerosis development in the low-density lipoprotein receptor knockout mouse.

79 on in lymphatic organs, and atherogenesis in low-density lipoprotein receptor knockouts were unaltere

80 with mPges-1 on a hyperlipidemic background (low-density lipoprotein receptor knockouts).

81 when MacKOs were crossed into hyperlipidemic low-density lipoprotein receptor knockouts.

82 moxifen exerts an atheroprotective action on low density lipoprotein receptor (LDL-r(-/-)) female mic

83 Investigation on the role of low-density lipoprotein receptor (LDL-R) as a hepatocyte

84 K9) down-regulates surface expression of the low-density lipoprotein receptor (LDL-R), increasing ser

85 ls was transplanted into lethally irradiated low density lipoprotein receptor Ldlr(-/-) mice on an at

86 a1(-/-) mice to mice that do not express the low density lipoprotein receptor (Ldlr(-/-)), which are

87 3 ubiquitin ligase-inducible degrader of the low density lipoprotein receptor (LDLR) (Idol) as a post

88 PCSK9 binds to the low density lipoprotein receptor (LDLR) and leads to LDL

89 epidermal growth factor-like-A domain of the low density lipoprotein receptor (LDLR) and mediates LDL

90 ted sdAbs efficiently blocked PCSK9-mediated low density lipoprotein receptor (LDLR) degradation in c

91 at CCP size and dynamic behavior varies with low density lipoprotein receptor (LDLR) expression level

92 bind heparin and receptors belonging to the low density lipoprotein receptor (LDLR) family, known to

93 The low density lipoprotein receptor (LDLR) is crucial for c

94 cholesterol regulation through modulation of low density lipoprotein receptor (LDLR) levels.

95 The low density lipoprotein receptor (LDLR) plays a key role

96 Low density lipoprotein receptor (LDLR) was shown to med

97 To inhibit recognition of oxLDL by KCs, low-density lipoprotein receptor (Ldlr(-/-) ) mice were

98 Mice fed a Western-type diet and lacking low-density lipoprotein receptor (Ldlr(-/-)T39(-/-)) sho

99 because of loss-of-function mutations in the low-density lipoprotein receptor (LDLR) and homozygous f

100 The effect of the treatments on cellular low-density lipoprotein receptor (LDLR) and proprotein c

101 in genetically deficient iPSC utilizing the low-density lipoprotein receptor (LDLR) deficiency Famil

102 Female low-density lipoprotein receptor (Ldlr) deficient mice w

103 ent-type ligand-binding repeats (CRs) in the low-density lipoprotein receptor (LDLR) family are thoug

104 to adopt active conformations for binding to low-density lipoprotein receptor (LDLR) family.

105 PSCs from JD a patient with mutations in the low-density lipoprotein receptor (LDLR) gene that result

106 le nucleotide polymorphism in exon 12 of the low-density lipoprotein receptor (LDLR) gene, rs688, has

107 which cystathionine beta-synthase (CBS) and low-density lipoprotein receptor (LDLr) genes were defic

108 of cholesterol and an overexpression of the low-density lipoprotein receptor (LDLR) in pancreatic tu

109 Low-density lipoprotein receptor (LDLR) internalization

110 The low-density lipoprotein receptor (LDLR) is a critical de

111 We recently demonstrated that the low-density lipoprotein receptor (LDLR) is a major apoE

112 Therefore, the low-density lipoprotein receptor (LDLR) is a relevant ta

113 Low-density lipoprotein receptor (LDLR) is involved in u

114 ime in atherosclerotic lesion macrophages of low-density lipoprotein receptor (Ldlr) knockout mice fe

115 e crossed Gsk3a/GSK3alpha-knockout mice with low-density lipoprotein receptor (Ldlr) knockout mice.

116 r risk for patients who already have reduced low-density lipoprotein receptor (LDLR) levels, such as

117 The hepatic low-density lipoprotein receptor (LDLR) pathway is essen

118 The low-density lipoprotein receptor (LDLR) plays a pivotal

119 Low-density lipoprotein receptor (LDLR) rs6511720 A was

120 Since the low-density lipoprotein receptor (LDLR) was recently ide

121 Moreover, when mice deficient in low-density lipoprotein receptor (LDLR) were bone-marrow

122 erized a novel mouse model, middle-aged male low-density lipoprotein receptor (LDLR)(-/-) mice fed a

123 Low-density lipoprotein receptor (LDLR)(-/-) mice with S

124 we demonstrate that modulating levels of the low-density lipoprotein receptor (LDLR), a cell surface

125 2 (Dab2) recruits its cargoes, including the low-density lipoprotein receptor (LDLR), and mediates en

126 At low-density lipoprotein receptor (LDLR), carriers of rar

127 at for one of the identified substrates, the low-density lipoprotein receptor (LDLR), ERdj5 is requir

128 audin-1 (CLDN1), Occludin (OCLN), SR-BI, and low-density lipoprotein receptor (LDLR), function mainly

129 tercellular adhesion molecule-1 (ICAM-1) and low-density lipoprotein receptor (LDLR), inter- and intr

130 s, we identified 2 nonsynonymous variants in low-density lipoprotein receptor (LDLR), namely p.G116S

131 ceptor/coreceptor molecules CD81, claudin-1, low-density lipoprotein receptor (LDLr), occludin, and S

132 ertase subtilisin/kexin type 9 (PCSK9) binds low-density lipoprotein receptor (LDLR), preventing its

133 As proof-of-principle, we targeted the low-density lipoprotein receptor (Ldlr), which when dele

134 rmone (PTH) inhibits aortic calcification in low-density lipoprotein receptor (LDLR)-deficient mice f

135 mice, apolipoprotein E (apoE)-deficient and low-density lipoprotein receptor (LDLR)-deficient mice t

136 receptor tyrosine-protein kinase), and Lrp4 (low-density lipoprotein receptor (LDLR)-related protein

137 We previously demonstrated that macrophage low-density lipoprotein receptor (LDLR)-related protein

138 ACAT), ACAT2, small heterodimer partner, and low-density lipoprotein receptor (LDLR)-related proteins

139 caused by loss-of-function mutations in the low-density lipoprotein receptor (LDLR).

140 e 9 (PCSK9) and regulate its activity on the low-density lipoprotein receptor (LDLR).

141 LDL (low-density lipoprotein) receptor (LDLR) binds to its ne

142 n (MYLIP, aka IDOL and inducible degrader of low-density lipoprotein receptor [LDLR]), with LDL chole

143 th controls, concomitant with an increase in low density lipoprotein receptors (LDLRs).

144 els through a mechanism that is dependent on low-density lipoprotein receptors (LDLRs) and LDLR-relat

145 its role in clathrin-mediated endocytosis of low-density lipoprotein receptors (LDLRs).

146 eased plasma PCSK9 levels, increased hepatic low-density lipoprotein receptor levels, and decreased p

147 binding assay showed that SERPINA3K binds to low-density lipoprotein receptor-like protein 6 (LRP6) w

148 Low-density lipoprotein receptors (LRPs) are present ext

149 xpression was analyzed in aortic arches from low density lipoprotein receptor(-/-) mice consuming a h

150 P2X7(+/+) and P2X7(-/-) low density lipoprotein receptor(-/-) mice were fed a hi

151 were transplanted into irradiated recipient low-density lipoprotein receptor(-/-) mice, and atherosc

152 Very low-density lipoprotein receptor mutant mice (Vldlr(-/-)

153 in apolipoprotein-deficient (apoE(-/-)) and low-density lipoprotein receptor negative (LDLR(-/-)) mi

154 Low-density lipoprotein receptor null mice in which Treg

155 METHODS AND Paradoxically, Ldlr(-/-) (low-density lipoprotein receptor null) mice deficient in

156 clerotic lesion size was found in Ldlr(-/-) (low-density lipoprotein receptor null) mice transplanted

157 hages worsened atherosclerosis in irradiated low-density lipoprotein receptor null-recipient mice and

158 Low density lipoprotein receptor-null (Ldlr(-/-)) mice o

159 en by a SM22Cre-IKKbeta-flox system rendered low density lipoprotein receptor-null mice resistant to

160 eficiency on experimental atherosclerosis in low-density lipoprotein receptor-null mice (Ldlr(-/-)).

161 We observed that atherosclerosis in low-density lipoprotein receptor-null mice progressed wh

162 n the vascular smooth muscle lineage of male low-density lipoprotein receptor-null mice, a background

163 evelopment of established atherosclerosis in low-density lipoprotein receptor-null mice.

164 APP chimeras harboring targeting motifs from low-density lipoprotein receptor or neuron-glia cell-adh

165 ncrease in permeability, whereas blockade of low-density lipoprotein receptors or exposed lysine resi

166 d via the liver provided that an intact apoE-low-density lipoprotein receptor pathway is present.

167 In parallel, the low-density-lipoprotein receptor plays a predominant rol

168 se subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor protein levels by diver

169 Low-density lipoprotein receptor protein 1 exerts antiat

170 L mice showed dramatic reductions in hepatic low-density lipoprotein receptor protein and increased p

171 ntibodies developed in these mice, LDLR(-/-)/low-density lipoprotein receptor Rag 1 double-knockout m

172 In LDLR(-/-)/low-density lipoprotein receptor Rag 1 double-knockout m

173 IDOL pathway in the liver can override other low-density lipoprotein receptor regulatory pathways lea

174 endent internalization of Abeta bound to the low density lipoprotein receptor related protein-1, a ke

175 complex formation involves Frizzled4 (Fz4), low-density lipoprotein receptor related protein 5/6 (Lr

176 ckkopf2 (Dkk1/2), to their cognate receptor, low-density-lipoprotein-receptor related protein 6 (LRP6

177 Low density lipoprotein receptor-related protein (LRP1)

178 We achieve this by targeting the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-

179 Low density lipoprotein receptor-related protein 1 (LRP1

180 und that ADAMTS-5 is rapidly endocytosed via low density lipoprotein receptor-related protein 1 (LRP1

181 In addition to its endocytic function, the low density lipoprotein receptor-related protein 1 (LRP1

182 The low density lipoprotein receptor-related protein 1 (LRP1

183 The low density lipoprotein receptor-related protein 1 (LRP1

184 ndocytic clearance by the scavenger receptor low density lipoprotein receptor-related protein 1 (LRP1

185 htly to the clearance and signaling receptor low density lipoprotein receptor-related protein 1 (LRP1

186 The low density lipoprotein receptor-related protein 1 (LRP1

187 LRP1 (low density lipoprotein receptor-related protein 1) was

188 ent increases mRNA and protein expression of low density lipoprotein receptor-related protein 2 and a

189 served amino acid position (p.R1188W) in the low density lipoprotein receptor-related protein 5 (LRP5

190 ted Wnt with its receptors Frizzled (Fz) and low density lipoprotein receptor-related protein 5/6 (LR

191 morphogenesis gene 2, as well as coreceptor low density lipoprotein receptor-related protein 6 (LRP6

192 ay genes, such as frizzled homolog 7 (FZD7), low density lipoprotein receptor-related protein 6 and t

193 receptor-associated protein (an inhibitor of low density lipoprotein receptor-related protein functio

194 tic receptor alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein in the

195 hosphorylation of eNOS was decreased by anti-low density lipoprotein receptor-related protein-1 (LRP)

196 es, and we found that the endocytic receptor low density lipoprotein receptor-related protein-1 (LRP-

197 We recently identified low density lipoprotein receptor-related protein-1 (LRP1

198 oligomers was dependent on the transmembrane low density lipoprotein receptor-related protein-1 (LRP1

199 The low density lipoprotein receptor-related protein-1 (LRP1

200 We investigated the role of low density lipoprotein receptor-related protein-1 (LRP1

201 ent and activation of beta1 integrin via the low density lipoprotein receptor-related protein-1 (LRP1

202 Soluble low density lipoprotein receptor-related protein-1 (sLRP

203 g to two receptors, the single transmembrane low density lipoprotein receptor-related proteins 5 and

204 bind to two distinct receptors, namely, the low-density lipoprotein receptor-related protein (LRP) a

205 Enhanced expression of low-density lipoprotein receptor-related protein (LRP) i

206 We previously reported that RanBP9 binds low-density lipoprotein receptor-related protein (LRP),

207 ng phospholipids, von Willebrand factor, and low-density lipoprotein receptor-related protein (LRP).

208 e largest member of the LDL receptor family, low-density lipoprotein receptor-related protein (LRP1).

209 Low-density lipoprotein receptor-related protein 1 (LRP-

210 Blocking low-density lipoprotein receptor-related protein 1 (LRP-

211 Blocking studies of low-density lipoprotein receptor-related protein 1 (LRP1

212 llaries was associated with its reduction in low-density lipoprotein receptor-related protein 1 (LRP1

213 t portion of apoE and sAbeta compete for the low-density lipoprotein receptor-related protein 1 (LRP1

214 An Abeta clearance receptor, the low-density lipoprotein receptor-related protein 1 (LRP1

215 Low-density lipoprotein receptor-related protein 1 (LRP1

216 e has demonstrated significant roles for the low-density lipoprotein receptor-related protein 1 (LRP1

217 , the receptors for these secreted proteins, low-density lipoprotein receptor-related protein 1 (LRP1

218 he deletion of a major lipoprotein receptor, low-density lipoprotein receptor-related protein 1 (LRP1

219 ed MvEC required expression of GRP78 and the low-density lipoprotein receptor-related protein 1 (LRP1

220 The low-density lipoprotein receptor-related protein 1 (LRP1

221 tween BKCaand both alpha2M and its receptor, low-density lipoprotein receptor-related protein 1 (LRP1

222 ction with the endocytic scavenger receptor, low-density lipoprotein receptor-related protein 1 (LRP1

223 pericytes also requires the function of the low-density lipoprotein receptor-related protein 1 (LRP1

224 s isoform-specific interactions of apoE with low-density lipoprotein receptor-related protein 1 on br

225 ASA-ApoE-II, uptake was partially due to the low-density lipoprotein receptor-related protein 1.

226 jects have identified autoantibodies against low-density lipoprotein receptor-related protein 4 (LRP4

227 tenance of neuromuscular synapses, and (iii) low-density lipoprotein receptor-related protein 4 (Lrp4

228 ctin, a protein acting downstream from agrin/low-density lipoprotein receptor-related protein 4 (LRP4

229 se in the brain was impaired in mice lacking low-density lipoprotein receptor-related protein 4 (Lrp4

230 We identified previously in vitro LRP4 (low-density lipoprotein receptor-related protein 4) as a

231 -derived protein, which interacts with LRP4 (low-density lipoprotein receptor-related protein 4) to a

232 ancer have identified novel functions of the low-density lipoprotein receptor-related protein 4-muscl

233 e human skeleton is affected by mutations in low-density lipoprotein receptor-related protein 5 (LRP5

234 Mesd is a specialized chaperone for low-density lipoprotein receptor-related protein 5 (LRP5

235 ptions of tryptophan hydroxylase 1 (Tph1) or low-density lipoprotein receptor-related protein 5 (Lrp5

236 Wnt signaling ligand or receptors, including low-density lipoprotein receptor-related protein 5 (LRP5

237 in Lrp5(ACT) mice in which a mutation in the low-density lipoprotein receptor-related protein 5 Wnt c

238 riched around the Wnt-activated Frizzled and low-density lipoprotein receptor-related protein 5/6 rec

239 The low-density lipoprotein receptor-related protein 6 (LRP6

240 Additionally, inhibition of low-density lipoprotein receptor-related protein 6 (LRP6

241 a critical chaperone for the Wnt coreceptor low-density lipoprotein receptor-related protein 6 (LRP6

242 Interactions between Cav-1 and low-density lipoprotein receptor-related protein 6 (LRP6

243 ation, where it binds to the Wnt co-receptor low-density lipoprotein receptor-related protein 6 (LRP6

244 quires caveolin-dependent internalization of low-density lipoprotein receptor-related protein 6 (LRP6

245 nin signaling pathway by down-regulating the low-density lipoprotein receptor-related protein 6 (LRP6

246 ical Wnt ligand Wnt3a and the Wnt coreceptor low-density lipoprotein receptor-related protein 6 (LRP6

247 Low-density lipoprotein receptor-related protein 6 (LRP6

248 t signaling by binding to the Wnt coreceptor low-density lipoprotein receptor-related protein 6 (LRP6

249 to determine contributions of Wnt coreceptor low-density lipoprotein receptor-related protein 6 (LRP6

250 ecific for the E1E2 domain of Wnt coreceptor low-density lipoprotein receptor-related protein 6, Mab2

251 itatory synapse number were mediated via the low-density lipoprotein receptor-related protein and sub

252 se domain 9 (ADAM9), reticulon 4 (RTN4), and low-density lipoprotein receptor-related protein associa

253 eted frizzled-related protein, Dickkopf, and low-density lipoprotein receptor-related protein gene fa

254 The low-density lipoprotein receptor-related protein recepto

255 sense substitutions within LRP1B, encoding a low-density lipoprotein receptor-related protein tied to

256 nt of interaction of mutants with either the low-density lipoprotein receptor-related protein, Lrp4 (

257 Low-density lipoprotein receptor-related protein-1 (LRP1

258 ple receptors including mannose receptor and low-density lipoprotein receptor-related protein-1 (LRP1

259 The relationship between low-density lipoprotein receptor-related protein-1 (LRP1

260 rocytic thrombospondin-1 (TSP1) and synaptic low-density lipoprotein receptor-related protein-1 (LRP1

261 Low-density lipoprotein receptor-related protein-1 (LRP1

262 (LPS) by a pathway that apparently requires low-density lipoprotein receptor-related protein-1 (LRP1

263 the neurovascular hypothesis, impairment of low-density lipoprotein receptor-related protein-1 (LRP1

264 Angiopep-2 (ANG), a ligand for the low-density lipoprotein receptor-related protein-1 (LRP1

265 rocytic thrombospondin-1 (TSP1) and synaptic low-density lipoprotein receptor-related protein-1 (LRP1

266 PDE1C interacts with low-density lipoprotein receptor-related protein-1 and P

267 alytic hemopexin domain of MMP9 binds to the low-density lipoprotein receptor-related protein-1, trig

268 sis and lysosome-dependent degradation in an low-density lipoprotein receptor-related protein-1-depen

269 -dependent PDGFRbeta protein degradation via low-density lipoprotein receptor-related protein-1.

270 y, we show that Wnt receptors (Frizzled4 and low-density lipoprotein receptor-related protein5 [Lrp5]

271 n (RAP), a ligand-binding antagonist for the low-density lipoprotein receptor-related proteins (LRPs)

272 1 (DKK-1), a ligand for the WNT coreceptors low-density lipoprotein receptor-related proteins 5 and

273 receptors frizzled 1-10 and the co-receptors low-density lipoprotein receptor-related proteins 5 and

274 Retinal levels of low-density lipoprotein receptor-related proteins 5 and

275 e frizzled receptor (FZD) and the coreceptor low-density lipoprotein-receptor-related protein 5 (LRP5

276 loci, rs1466535, located within intron 1 of low-density-lipoprotein receptor-related protein 1 (LRP1

277 Fetal liver cells derived from low-density-lipoprotein receptor-related protein 6-defic

278 Here we show that the soluble form of the low-density lipoprotein receptor relative, LR11/SorLA (s

279 via apolipoprotein E receptor 2 and the very low density lipoprotein receptor, resulting in the phosp

280 Drosophila vitellogenin receptor Yolkless, a low density lipoprotein receptor superfamily member, occ

281 LR11, also known as SorLA, is a mosaic low-density lipoprotein receptor that exerts multiple in

282 teraction with the RELN receptor VLDLR (very low-density lipoprotein receptor); this was confirmed by

283 These antibodies prevent the degradation of low density lipoprotein receptor, thus lowering serum le

284 thereby preventing the recirculation of the low-density lipoprotein receptor to the hepatocyte cell

285 ch region (aa 95-141) that separates the two low-density lipoprotein receptor type A (LDLR-A) domains

286 Activation of very low density lipoprotein receptor (VLDLR) and apolipoprot

287 n signals via the lipoprotein receptors very low density lipoprotein receptor (VLDLR) and apolipoprot

288 polipoprotein E receptor 2 (ApoER2) and very low density lipoprotein receptor (VLDLR) and is internal

289 We discovered that miR-200c targets the very low density lipoprotein receptor (Vldlr) and its ligand

290 ApoE Receptor 2 (ApoER2) and the very low density lipoprotein receptor (VLDLR) are type I tran

291 The very low density lipoprotein receptor (VLDLR) is a member of

292 Previously, we have shown that very low density lipoprotein receptor (VLDLR) is virtually ab

293 ed choroidal neovascularization and the very low density lipoprotein receptor (Vldlr)-knockout mouse]

294 led a point mutation, c.2239C>T, in the very-low-density lipoprotein receptor (Vldlr) gene.

295 Very-low-density lipoprotein receptor (VLDLR) is a multi liga

296 The very-low-density lipoprotein receptor (VLDLR) negatively regu

297 thways including through the receptors, Very low-density lipoprotein receptor (Vldlr), Apolipoprotein

298 e deficient in another Reelin receptor, very low-density lipoprotein receptor (VLDLR), had normal rod

299 Very-low-density lipoprotein receptor (Vldlr), which is prese

300 nopathy and another angiogenic model of very-low-density lipoprotein receptor (Vldlr)-deficient (Vldl

301 ion disrupts an interaction with VLDLR (very low-density lipoprotein receptor), while the APOER2 sign